Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes

Toxicology in Vitro

Volumn 34, Issue , 2016, Pages 179-186

  Oorts, Marlies ^a,b   Baze, Audrey ^b   Bachellier, Philippe ^c,d   Heyd, Bruno ^c,e   Zacharias, Thomas ^f   Annaert, Pieter ^a   Richert, Lysiane ^b,c  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b KaLy Cell   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f Hôpitaux Universitaires de Strasbourg   (France)

Author keywords

Bile acids; Drug induced cholestasis; Hepatotoxicity; In vitro model; MIP DILI set of training compounds; Sandwich cultured human hepatocytes

Indexed keywords

AMIODARONE; BILE ACID; BOSENTAN; BUSPIRONE; CYCLOSPORIN A; DICLOFENAC; ENTACAPONE; FIALURIDINE; METFORMIN; NEFAZODONE; PARACETAMOL; PERHEXILINE; PIOGLITAZONE; TOLCAPONE; TROGLITAZONE; UREA; XIMELAGATRAN; CYCLOSPORIN;

ARTICLE; CHOLESTASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DRUG CYTOTOXICITY; DRUG INDUCED CHOLESTASIS INDEX; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CULTURE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SANDWICH CULTURED HUMAN HEPATOCYTE; TOXIC HEPATITIS; UREA CYCLE; VALIDATION STUDY; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER CELL; METABOLISM; PROCEDURES;

BILE ACIDS AND SALTS; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHOLESTASIS; CYCLOSPORINE; HEPATOCYTES; HUMANS; RISK ASSESSMENT; UREA;

EID: 84964329655     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2016.03.008     Document Type: Article

References (67)

1. Ashrafian H., Horowitz J.D., Frenneaux M.P. Perhexiline. Cardiovasc. Drug Rev. 2007, 10.1111/j.1527-3466.2007.00006.x.
2. Ballatori N., Christian W.V., Lee J.Y., Dawson P.A., Soroka C.J., Boyer J.L., Madejczyk M.S., Li N. OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005, 42:1270-1279. 10.1002/hep.20961.
3. Boelsterli U.A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 2003, 10.1016/S0041-008X(03)00368-5.
4. Bohan A., Boyer J.L. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin. Liver Dis. 2002, 10.1055/s-2002-30099.
5. Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin. Drug Saf. 2005, 4:69-73. 10.1517/14740338.4.1.69.
6. Brackett C.C. Clarifying metformin's role and risks in liver dysfunction. J. Am. Pharm. Assoc. 2010, 2003(50):407-410. 10.1331/JAPhA.2010.08090.
7. Bunchorntavakul C., Reddy K.R. Acetaminophen-related hepatotoxicity. Clin. Liver Dis. 2013, 10.1016/j.cld.2013.07.005.
8. Chatterjee S., Bijsmans I.T.G.W., van Mil S.W.C., Augustijns P., Annaert P. Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates. Toxicol. In Vitro 2014, 28:218-230. 10.1016/j.tiv.2013.10.020.
9. Chatterjee S., Richert L., Augustijns P., Annaert P. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. Toxicol. Appl. Pharmacol. 2014, 274:124-136. 10.1016/j.taap.2013.10.032.
10. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005, 10.1002/hep.20567.
11. Dawson S., Stahl S., Paul N., Barber J., Kenna J.G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 2012, 40:130-138. 10.1124/dmd.111.040758.
12. De Bruyn T., Chatterjee S., Fattah S., Keemink J., Nicolaï J., Augustijns P., Annaert P. Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 2013, 9:589-616. 10.1517/17425255.2013.773973.
13. Dhillon S., Keating G.M. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am. J. Cardiovasc. Drugs 2009, 9:331-350. 10.2165/11202270-000000000-00000.
14. Maillette de BuyWenniger L., Beuers U. Bile salts and cholestasis. Dig. Liver Dis. 2010, 10.1016/j.dld.2010.03.015.
15. Dykens J.a, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 2007, 12:777-785. 10.1016/j.drudis.2007.07.013.
16. Dykens J.A., Jamieson J.D., Marroquin L.D., Nadanaciva S., Xu J.J., Dunn M.C., Smith A.R., Will Y. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 2008, 103:335-345. 10.1093/toxsci/kfn056.
17. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., Meier P.J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 2001, 69:223-231. 10.1067/mcp.2001.114667.
18. Fischer S., Beuers U., Spengler U., Zwiebel F.M., Koebe H.G. Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. Clin. Chim. Acta 1996, 251:173-186.
19. Fisher A., Croft-Baker J., Davis M., Purcell P., McLean A.J. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov. Disord. 2002, 17:1362-1365. 10.1002/mds.10342.
20. Flaharty K.K., Chase S.L., Yaghsezian H.M., Rubin R. Hepatotoxicity associated with amiodarone therapy. Pharmacotherapy 1989.
21. Floyd J.S., Barbehenn E., Lurie P., Wolfe S.M. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol. Drug Saf. 2009, 18:1238-1243. 10.1002/pds.1804.
22. Francis C.W. Ximelagatran: a new oral anticoagulant. Best Pract. Res. Clin. Haematol. 2004, 17:139-152. 10.1016/j.beha.2004.03.005.
23. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 1995, 67:101-154. 10.1016/0163-7258(95)00012-6.
24. Fukuda Y., Takenaka K., Sparreboom A., Cheepala S.B., Wu C.-P., Ekins S., Ambudkar S.V., Schuetz J.D. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol. Pharmacol. 2013, 84:361-371. 10.1124/mol.113.086967.
25. Funk C., Pantze M., Jehle L., Ponelle C., Scheuermann G., Lazendic M., Gasser R. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt. Toxicology 2001, 167:83-98.
26. Gnewuch C. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J. Gastroenterol. 2009, 15:3134. 10.3748/wjg.15.3134.
27. Kaplowitz N.D.L.D. Drug-induced Liver Disease 2013, Academic Press. second ed.
28. Keisu M., Andersson T.B. Drug-induced liver injury in humans: the case of ximelagatran. Handb. Exp. Pharmacol. 2010, 196:407-418. 10.1007/978-3-642-00663-0_13.
29. Kenna J.G., Stahl S.H., Eakins J.a., Foster A.J., Andersson L.C., Bergare J., Billger M., Elebring M., Elmore C.S., Thompson R.a. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists. J. Pharmacol. Exp. Ther. 2014, 352:281-290. 10.1124/jpet.114.220491.
30. Kenne K., Skanberg I., Glinghammar B., Berson A., Pessayre D., Flinois J.-P., Beaune P., Edebert I., Pohl C.D., Carlsson S., Andersson T.B. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol. In Vitro 2008, 22:730-746. 10.1016/j.tiv.2007.11.014.
31. Kis E., Ioja E., Rajnai Z., Jani M., Méhn D., Herédi-Szabó K., Krajcsi P. BSEP inhibition: in vitro screens to assess cholestatic potential of drugs. Toxicol. In Vitro 2012, 26:1294-1299. 10.1016/j.tiv.2011.11.002.
32. Kleiner D.E., Gaffey M.J., Sallie R., Tsokos M., Nichols L., McKenzie R., Straus S.E., Hoofnagle J.H. Histopathologic changes associated with fialuridine hepatotoxicity. Mod. Pathol. 1997, 10:192-199.
33. Kock K., Ferslew B.C., Netterberg I., Yang K., Urban T.J., Swaan P.W., Stewart P.W., Brouwer K.L. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters MRP3 and MRP4. Drug Metab. Dispos. 2013, 10.1124/dmd.113.054304.
34. Kostrubsky S.E., Strom S.C., Kalgutkar A.S., Kulkarni S., Atherton J., Mireles R., Feng B., Kubik R., Hanson J., Urda E., Mutlib A.E. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 2006, 90:451-459. 10.1093/toxsci/kfj095.
35. Kubitz R., Dröge C., Stindt J., Weissenberger K., Häussinger D. The bile salt export pump (BSEP) in health and disease. Clin. Res. Hepatol. Gastroenterol. 2012, 36:536-553. 10.1016/j.clinre.2012.06.006.
36. Larson A.M. Acetaminophen hepatotoxicity. Clin. Liver Dis. 2007, 10.1016/j.cld.2007.06.006.
37. Lebovitz H.E., Kreider M., Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002, 25:815-821.
38. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003, 349:474-485. 10.1056/NEJMra021844.
39. Lee W.M., Larrey D., Olsson R., Lewis J.H., Keisu M., Auclert L., Sheth S. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005, 28:351-370. 10.2165/00002018-200528040-00006.
40. Manning F.J., Swartz M. Review of the Fialuridine (FIAU) Clinical Trials 1995.
41. Marion T.L., Leslie E.M., Brouwer K.L.R. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol. Pharm. 2007, 10.1021/mp0700357.
42. McGill M.R., Sharpe M.R., Williams C.D., Taha M., Curry S.C., Jaeschke H. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J. Clin. Invest. 2012, 122:1574-1583. 10.1172/JCI59755.
43. McKenzie R., Fried M.W., Sallie R., Conjeevaram H., Di Bisceglie A.M., Park Y., Savarese B., Kleiner D., Tsokos M., Luciano C. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England J. Med. 1995, 10.1056/NEJM199510263331702.
44. Miralles-Linares F., Puerta-Fernandez S., Bernal-Lopez M.R., Tinahones F.J., Andrade R.J., Gomez-Huelgas R. Metformin-induced hepatotoxicity. Diabetes Care 2012, 35:e21. 10.2337/dc11-2306.
45. Morgan R.E., Trauner M., van Staden C.J., Lee P.H., Ramachandran B., Eschenberg M., Afshari C.a, Qualls C.W., Lightfoot-Dunn R., Hamadeh H.K. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 2010, 118:485-500. 10.1093/toxsci/kfq269.
46. Olanow C.W. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch. Neurol. 2000, 10.1001/archneur.57.2.263.
47. Oorts M., Richert L., Annaert P. Drug-induced cholestasis detection in cryopreserved rat hepatocytes in sandwich culture. J. Pharmacol. Toxicol. Methods 2015, 73:63-71. 10.1016/j.vascn.2015.03.002.
48. Padda M.S., Sanchez M., Akhtar A.J., Boyer J.L. Drug-induced cholestasis. Hepatology 2011, 53:1377-1387. 10.1002/hep.24229.
49. Pauli-Magnus C., Meier P.J. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006, 44:778-787. 10.1002/hep.21359.
50. Pedersen J.M., Matsson P., Bergström C.A.S., Hoogstraate J., Norén A., LeCluyse E.L., Artursson P. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol. Sci. 2013, 136:328-343. 10.1093/toxsci/kft197.
51. Perez M.J. Bile-acid-induced cell injury and protection. World J. Gastroenterol. 2009, 15:1677. 10.3748/wjg.15.1677.
52. Alrefai W.a, Gill R.K. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 2007, 24:1803-1823. 10.1007/s11095-007-9289-1.
53. Rouru J., Gordin A., Huupponen R., Huhtala S., Savontaus E., Korpela K., Reinikainen K., Scheinin M. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Eur. J. Clin. Pharmacol. 1999, 55:461-467. 10.1007/s002280050657.
54. Scherer M., Gnewuch C., Schmitz G., Liebisch G. Rapid quantification of bile acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877:3920-3925. 10.1016/j.jchromb.2009.09.038.
55. Sergent O., Ekroos K., Lefeuvre-Orfila L., Rissel M., Forsberg G.-B., Oscarsson J., Andersson T.B., Lagadic-Gossmann D. Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol. In Vitro 2009, 23:1305-1310. 10.1016/j.tiv.2009.07.019.
56. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 2003, 16:679-687. 10.1021/tx034033e.
57. Unzueta A., Vargas H.E. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin. Liver Dis. 2013, 10.1016/j.cld.2013.07.009.
58. Van den Hof W.F.P.M., Ruiz-Aracama A., Van Summeren A., Jennen D.G., Gaj S., Coonen M.L., Brauers K., Wodzig W.K., Kleinjans J.C., Van Delft J. Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. BMC Syst. Biol. Submitted. 2014, 10.1016/j.tiv.2014.12.016.
59. Watkins P. COMT inhibitors and liver toxicity. Neurology 2000, 55:S51-S52. (discussion S53-S56).
60. Xiang X., Han Y., Neuvonen M., Laitila J., Neuvonen P.J., Niemi M. High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2010, 878:51-60. 10.1016/j.jchromb.2009.11.019.
61. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D., Graaf D.De Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105. 10.1093/toxsci/kfn109.
62. Xu D., Nishimura T., Nishimura S., Zhang H., Zheng M., Guo Y.Y., Masek M., Michie S.A., Glenn J., Peltz G. fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med. 2014, 11. 10.1371/journal.pmed.1001628.
63. Yamazaki M., Miyake M., Sato H., Masutomi N., Tsutsui N., Adam K.-P., Alexander D.C., Lawton K.a, Milburn M.V., Ryals J.a, Wulff J.E., Guo L. Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol. Appl. Pharmacol. 2013, 268:79-89. 10.1016/j.taap.2013.01.018.
64. Yang K., Köck K., Sedykh A., Tropsha A., Brouwer K.L.R. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J. Pharm. Sci. 2013, 102:3037-3057. 10.1002/jps.23584.
65. Yao X., Anderson D.L., Ross S.A., Lang D.G., Desai B.Z., Cooper D.C., Wheelan P., McIntyre M.S., Bergquist M.L., MacKenzie K.I., Becherer J.D., Hashim M.A. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 2008, 154:1446-1456. 10.1038/bjp.2008.267.
66. Yu L., von Bergmann K., Lutjohann D., Hobbs H.H., Cohen J.C. Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J. Lipid Res. 2004, 45:301-307. 10.1194/jlr.M300377-JLR200.
67. Zhang F., Xue J., Shao J., Jia L. Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discov. Today 2012, 10.1016/j.drudis.2011.12.018.